{"gene":"SAA1","run_date":"2026-06-10T07:46:29","timeline":{"discoveries":[{"year":1977,"finding":"SAA protein is physically associated with high density lipoprotein HDL3 in human serum, co-sedimenting at density 1.12–1.21 g/cm3 with apolipoproteins ApoA-I and ApoA-II, and can be dissociated into low molecular weight species (~13,000 Da) under dissociating conditions.","method":"Sequential ultracentrifugation, density gradient fractionation, immunochemical analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct physical fractionation with density gradients, replicated across multiple subsequent studies","pmids":["198813"],"is_preprint":false},{"year":1977,"finding":"Low molecular weight SAA (~12,000 Da) self-aggregates and binds serum albumin but not IgG or Bence Jones proteins, forming ~85,000 Da and ~170,000 Da complexes under physiological conditions.","method":"Gel filtration with radiolabeled 125I-SAA, cold competition binding assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, direct binding experiment with radiolabeled protein, no replication cited","pmids":["301900"],"is_preprint":false},{"year":1982,"finding":"SAA synthesis in isolated mouse hepatocytes is induced in vitro by purified leukocytic pyrogen (LP/IL-1), demonstrating the liver as the direct target for cytokine-driven SAA production; colchicine treatment blocks SAA secretion and causes intracellular accumulation, indicating secretory pathway dependence.","method":"In vitro hepatocyte culture, immunoprecipitation, autoradiography, wheat-germ cell-free translation of hepatic mRNA","journal":"Annals of the New York Academy of Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro reconstitution with purified inducer, multiple orthogonal readouts (secretion blockade, cell-free translation), single lab","pmids":["6807176"],"is_preprint":false},{"year":1985,"finding":"SAA enrichment of HDL particles (up to 87% of HDL apolipoprotein) is associated with phospholipid depletion, increased triglyceride content, and larger particle size (radius 4.5–5.3 nm) at normal HDL3 density; this size-density dissociation was also reproduced by in vitro incubation of normal HDL with SAA.","method":"Sequential ultracentrifugation, SDS-PAGE, gradient gel electrophoresis, in vitro HDL-SAA incubation","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal biophysical methods, in vitro reconstitution confirming causal role of SAA, replicated in vivo and in vitro in same study","pmids":["4086942"],"is_preprint":false},{"year":1987,"finding":"Mouse peritoneal macrophages express the SAA3 gene exclusively (not SAA1 or SAA2), while liver co-expresses all three SAA genes; during accelerated amyloidosis, macrophage SAA3 expression increases as hepatic SAA1/SAA2 expression decreases, indicating distinct extrahepatic and tissue-specific regulation of SAA gene family members.","method":"Differential gene expression analysis (mRNA), comparative acute-phase induction models in mice","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple inflammatory models compared, tissue-specific mRNA expression with functional disease context, single lab","pmids":["3680951"],"is_preprint":false},{"year":1993,"finding":"SAA1 gamma isoform is characterized by alanines at both residues 52 and 57 (rather than valine at one position), representing a novel polymorphism; N-terminal des-Arg and des-Arg-Ser forms of all SAA1 subsets were identified, indicating common post-translational N-terminal processing.","method":"Ion-spray mass spectrometry, LC/fast atom bombardment mass spectrometry, collision-activated dissociation MS, amino acid analysis","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal mass spectrometry methods definitively characterizing protein sequence and PTM, single lab","pmids":["8512321"],"is_preprint":false},{"year":1997,"finding":"SAA1 (but not ApoA-I) enhances cyclooxygenase metabolite formation (TXA2, PGE2, PGF2α) in calcium ionophore-stimulated human monocytes in a dose-dependent manner; anti-SAA1 peptide (40-63) F(ab)2 fragments showed the proposed Ca2+-binding tetrapeptide (Gly48-Pro49-Gly50-Cys51) is not responsible, and SAA1 does not directly bind Ca2+ ions.","method":"In vitro monocyte stimulation, eicosanoid measurement, peptide antibody inhibition, Ca2+ binding assay","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assay with specific peptide inhibitors and negative Ca2+-binding result, single lab, multiple eicosanoid endpoints","pmids":["9428637"],"is_preprint":false},{"year":2000,"finding":"Mouse SAA1.1 is fibrillogenic in vitro and causes amyloid deposition in vivo when expressed via adenoviral vector in CE/J mice, while SAA2.2 (the composite isoform in CE/J mice) cannot form fibrils and does not induce amyloid; mixing SAA2.2 with SAA1.1 does not inhibit SAA1.1 fibrillogenesis, demonstrating that CE/J amyloid resistance is due to structural inability of SAA2.2 to form fibrils.","method":"Recombinant protein expression, in vitro fibril formation assay, adenoviral vector-mediated in vivo expression, amyloid induction model","journal":"Laboratory investigation","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of fibrillogenesis plus in vivo adenoviral expression with genetic isoform specificity, multiple orthogonal methods","pmids":["11140693"],"is_preprint":false},{"year":2000,"finding":"Transgenic overexpression of acute-phase SAA1.1 at moderate levels did not significantly alter ApoA-I or HDL cholesterol levels, but high-level adenoviral SAA1.1 expression produced ~10% larger HDL particles; constitutive SAA4 expression increased HDL size (~10%), VLDL levels (20-fold), and triglycerides (1.7-fold), indicating isoform-specific effects on lipoprotein metabolism.","method":"SAA1.1 transgenic mice with inducible metallothionein promoter, adenoviral vector overexpression, lipoprotein profiling","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — transgenic and adenoviral in vivo models with quantitative lipoprotein measurements, isoform comparison, single lab","pmids":["10845870"],"is_preprint":false},{"year":2003,"finding":"Glucocorticoids induce SAA1 transcription in KB epithelial cells but not in HepG2 hepatoma cells when administered alone; this glucocorticoid effect on SAA1 in both cell lines is glucocorticoid receptor-dependent, demonstrating tissue-specific and receptor-dependent transcriptional regulation of SAA1.","method":"RT-PCR mRNA quantification, glucocorticoid/cytokine treatments, receptor dependency analysis in hepatoma and epithelial cell lines","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — comparison across two cell types with receptor-dependency confirmation, single lab","pmids":["12938239"],"is_preprint":false},{"year":2006,"finding":"SAA activates human mast cells to produce TNF-α and IL-1β in a dose-dependent manner; mast cell tryptase (but not chymase) cleaves SAA to release a highly amyloidogenic N-terminal fragment; intact mast cells degrade SAA and generate protofibrillar intermediates, implicating mast cells in AA amyloidosis pathogenesis.","method":"HMC-1 cell culture with rhSAA, ELISA, gel electrophoresis, LC-MS for degradation products, electron microscopy for protofibril detection","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — enzymatic cleavage assay with purified proteases, MS identification of fragments, functional cytokine readout, single lab with multiple orthogonal methods","pmids":["16483749"],"is_preprint":false},{"year":2010,"finding":"CD36, a class B scavenger receptor, functions as an SAA receptor mediating SAA uptake and pro-inflammatory signaling; SAA (but not other apolipoproteins) induces 10–50-fold increase in IL-8 secretion in CD36-overexpressing HEK293 cells; SAA-mediated signaling is primarily through JNK and ERK1/2 MAPK pathways; cd36−/− rat macrophages show 60–75% reduction in SAA-induced cytokine secretion; HDL-associated SAA neutralizes the effect.","method":"Stable transfection of CD36 in HeLa/HEK293 cells, fluorescent SAA uptake assay, ELISA for cytokines, MAPK phosphorylation assay, NF-κB/MAPK inhibitor studies, cd36−/− rat macrophages/Kupffer cells, CD36 peptide blocking","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods including overexpression, knockout cells, inhibitors, and blocking peptides across multiple cell types, single lab with comprehensive evidence","pmids":["20075072"],"is_preprint":false},{"year":2012,"finding":"Lipid-poor (recombinant or purified) SAA stimulates pro-inflammatory cytokine (G-CSF) production in mouse J774 macrophages via TLR2, but HDL-associated SAA fails to stimulate cytokine production; in vivo adenoviral expression of mouse SAA in SAA-deficient mice did not elevate G-CSF at peak SAA levels, leaving physiological cytokine-inducing role of SAA in vivo ambiguous.","method":"J774 cell stimulation with lipid-poor rSAA and HDL-associated SAA, TLR2/4 neutralizing antibodies, adenoviral SAA expression in SAA-deficient mice, ELISA","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — TLR2 identified with neutralizing antibodies, in vivo adenoviral model, lipidation state comparison, single lab","pmids":["23165195"],"is_preprint":false},{"year":2014,"finding":"SAA promotes differentiation of human monocytes into a distinct CD11c(high)CD11b(high) macrophage phenotype in vitro and in vivo (mouse airway challenge model); ALX/FPR2 antagonist WRW4 reduced IL-6 and IL-1β but not phagocytic activity; blocking CSF-1R signaling reduced CD11c(high)CD11b(high) macrophages by 71% and neutrophilic inflammation by 80%, placing SAA-driven macrophage differentiation downstream of CSF-1R.","method":"Human monocyte culture with SAA, FPR2 antagonist (WRW4), CSF-1R inhibitor, BALB/c mouse airway SAA challenge, flow cytometry, ELISA","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition of two receptors in vitro and in vivo, defined macrophage phenotype by flow cytometry, single lab","pmids":["24846388"],"is_preprint":false},{"year":2014,"finding":"SAA1.1 and SAA1.3 isoforms, but not SAA1.5, suppress tumor formation and angiogenesis in nasopharyngeal carcinoma (NPC) cell lines in vitro and in vivo; secreted SAA1.1 and SAA1.3 block cell adhesion and induce apoptosis in vascular endothelial cells; SAA1.5 shows weaker binding affinity to αVβ3 integrin and lacks antiangiogenic/apoptotic function.","method":"Restoration of SAA1 isoforms in SAA1-deficient NPC cell lines, tumor formation assays in vitro/in vivo, endothelial cell apoptosis assay, αVβ3 integrin binding assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple isoforms tested, integrin binding assay, in vitro and in vivo tumor suppression, endothelial cell apoptosis, single lab with multiple orthogonal methods","pmids":["24608426"],"is_preprint":false},{"year":2016,"finding":"HDL counter-regulates SAA-induced sPLA2-IIE and sPLA2-V expression and secretion in murine macrophages in a dose-dependent manner; HDL also suppresses SAA-induced HMGB1 release, NO production, autophagy activation, and cytokine/chemokine secretion via TLR4-dependent signaling.","method":"RAW264.7 and primary macrophage culture, SAA and HDL treatment, ELISA, western blot for sPLA2 isoforms and signaling molecules, TLR4 functional dependence assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dose-dependent HDL counter-regulation shown for multiple endpoints, TLR4 dependence established, single lab","pmids":["27898742"],"is_preprint":false},{"year":2016,"finding":"Heparin interacts with both ApoA-I and SAA in HDL from inflamed mice, forming complex aggregates; mass spectrometry of crosslinked HDL-SAA particles detected multiple crosslinks between ApoA-I and SAA indicating close proximity (within 25 Å) on the HDL surface.","method":"Gel electrophoresis, chemical crosslinking, mass spectrometry of crosslinked peptides","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — crosslinking MS provides structural proximity data, single lab, limited functional validation","pmids":["27105909"],"is_preprint":false},{"year":2017,"finding":"SR-BII (splice variant of SR-BI) functions as an SAA receptor mediating SAA uptake (~3-fold increase) and pro-inflammatory IL-8 secretion (~3–3.5-fold increase) in transfected cells; SAA activates ERK1/2, p38, and JNK MAPK pathways via SR-BII; transgenic mice overexpressing hSR-BII showed ~2–5-fold higher inflammatory mediator expression in liver and kidney after SAA injection compared to wild-type.","method":"Stable transfection of hSR-BII in HeLa/HEK293 cells, fluorescent SAA uptake assay, ELISA, MAPK phosphorylation assay, transgenic mouse in vivo SAA challenge, histology, plasma transaminase measurement","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — overexpression and transgenic in vivo models, multiple signaling pathway readouts, in vitro and in vivo concordance, single lab","pmids":["28423002"],"is_preprint":false},{"year":2018,"finding":"COOH-terminal SAA1 fragments (SAA1(46-112) bovine; SAA1(47-104) human) fail to directly chemoattract leukocytes, induce chemokines, or stimulate ERK signaling, but potently synergize with CCL3 (monocyte migration) and CXCL8 (neutrophil chemotaxis) via FPR2; SAA1(47-104) desensitizes intact SAA1α/CXCL8 synergy, and WRW4 (FPR2 antagonist) completely blocks synergy, confirming FPR2 as the mediating receptor.","method":"Protein purification from bovine serum, chemical synthesis of peptides, chemotaxis assays, ERK signaling assay, FPR2 antagonist (WRW4) blocking, in vivo mouse peritoneal neutrophil recruitment assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — purified natural fragment plus synthetic peptide, multiple cell types, FPR2 receptor confirmed by receptor desensitization and antagonist, in vitro and in vivo concordance","pmids":["29371208"],"is_preprint":false},{"year":2019,"finding":"SAA1 increases NOX4/ROS production and activates the p38MAPK/NF-κB pathway to promote LPS-induced inflammatory cytokine release (IL-1β, IL-6, IL-8, IL-17, TNF-α, MCP-1) in vascular smooth muscle cells; both SAA1 siRNA and NOX4 siRNA attenuate this pathway, and combined knockdown shows no additive effect, placing SAA1 upstream of NOX4 in this signaling cascade.","method":"SAA1 siRNA, NOX4 siRNA, recombinant SAA1 protein treatment, lucigenin-enhanced chemiluminescence for O2− and NADPH oxidase activity, qRT-PCR, western blot for p38MAPK/NF-κB pathway proteins","journal":"BMC molecular and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via double knockdown placing SAA1 upstream of NOX4, pathway validated by western blot, single lab","pmids":["31216990"],"is_preprint":false},{"year":2019,"finding":"SAA1/Saa1 silencing inhibits palmitate-induced insulin resistance in Huh7 cells and HFD-induced insulin resistance in mice via suppression of the NF-κB pathway; SAA1 promotes NF-κB p65 nuclear translocation both in vitro and in vivo, linking SAA1 to hepatic insulin signaling impairment.","method":"SAA1 siRNA in Huh7 cells, HFD mouse model with Saa1 silencing, NF-κB inhibitor (BAY 11-7082), RT-qPCR, western blot, glucose tolerance test, insulin sensitivity assay, NF-κB p65 nuclear/cytoplasmic fractionation","journal":"Molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo concordant KD results, NF-κB p65 nuclear translocation directly measured, single lab","pmids":["31060494"],"is_preprint":false},{"year":2020,"finding":"Purified recombinant SAA1 (hrSAA1) free of LPS, lipoprotein, and formylated peptide contaminants retains leukocyte-recruiting capacity in vivo and synergy with other chemoattractants via FPR2, and promotes monocyte survival; however, hrSAA1 lacks most cytokine-inducing, MMP-9 release, ROS generation, and macrophage differentiation activities previously attributed to SAA1, indicating these TLR-mediated effects were due to bacterial contaminants in commercial rSAA1 preparations.","method":"RP-HPLC purification of rSAA1, endotoxin removal, chemotaxis assays, cytokine ELISA, MMP-9 measurement, ROS assay, macrophage differentiation, in vivo leukocyte recruitment, FPR2 activation assay","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous purification with removal of contaminants, multiple orthogonal functional assays, resolves contradictions in the field","pmids":["32477346"],"is_preprint":false},{"year":2020,"finding":"SAA1 is synthesized de novo in human placental villous trophoblasts; SAA1 expression increases upon syncytialization and with LPS, TNF-α, and cortisol treatment; SAA1 treatment of syncytiotrophoblasts increases IL-1β, IL-8, TNF-α, COX-2 expression and PGF2α production; intraperitoneal SAA1 injection in mice induces preterm birth and increases inflammatory mediators in placenta.","method":"RT-PCR, western blot, immunohistochemistry in human placenta; syncytialization cell model; cytokine ELISA; in vivo SAA1 injection mouse model with preterm birth readout","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo concordant results, specific inflammatory gene induction measured, single lab","pmids":["32582166"],"is_preprint":false},{"year":2021,"finding":"SAA1 acts as a hepatic endogenous chemokine for TLR2 on hepatic stellate cells (HSCs), recruiting them toward injury loci; SAA1/TLR2 signaling stimulates Rac GTPases through PI3K-dependent pathways, induces MLC phosphorylation (pSer19), and drives actin filament remodeling and directional migration; genetic TLR2 deletion and pharmacological PI3K inhibition both abolish MLCpSer19 phosphorylation and HSC migration.","method":"Gene manipulation (TLR2 knockout, SAA1 overexpression/knockdown) in cell and mouse models, PI3K pharmacological inhibition, MLC phosphorylation western blot, Rac GTPase activity assay, migration assay","journal":"iScience","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — genetic and pharmacological epistasis, defined signaling pathway with specific phosphorylation readout, in vitro and in vivo concordance, single lab","pmids":["34113824"],"is_preprint":false},{"year":2021,"finding":"SAA1 promotes intrahepatic platelet aggregation and liver inflammation in NAFLD; SAA1-treated platelets show increased aggregation sensitivity, activation, and adhesion partly via TLR2 signaling; SAA1 knockdown in vivo reduces intrahepatic platelet aggregation and ameliorates fatty liver inflammation in HFD mice.","method":"SAA1 recombinant protein platelet treatment, TLR2 inhibitor blocking, platelet aggregation/activation/adhesion assays, in vivo SAA1 knockdown in HFD mice, liver histology, inflammation markers","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — TLR2 dependence shown with inhibitor, in vitro and in vivo concordance, single lab","pmids":["33813276"],"is_preprint":false},{"year":2021,"finding":"SAA1 is transcriptionally activated by STAT3 and directly binds VIMP to inhibit the Derlin-1/VCP/VIMP complex, preventing misfolded protein degradation and causing endoplasmic reticulum stress (elevated GRP78), which promotes renal interstitial fibrosis.","method":"Bioinformatics prediction confirmed by SAA1 expression in UUO mouse model and TGF-β-induced HK2 cells, STAT3 ChIP/transcriptional activation assays, co-immunoprecipitation of SAA1 with VIMP, ER stress markers (GRP78), siRNA knockdown","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP binding partner identified, STAT3 transcriptional activation and downstream ER stress mechanism, single lab","pmids":["34597680"],"is_preprint":false},{"year":2021,"finding":"SAA1 promotes pro-labour inflammatory mediators (IL-8, IL-6, CXCL5, CCL2, ICAM1, ICAM5, COX-2, PGE2) in human primary myometrial cells through activation of the YAP (Yes-associated protein) pathway; SAA1 knockdown reduces phospho-YAP and downstream pro-inflammatory gene expression, while YAP overexpression reverses the knockdown effect.","method":"SAA1 siRNA in human primary myometrial cells, YAP overexpression rescue experiment, western blot for pYAP, cytokine/mediator ELISA and RT-PCR","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue (YAP overexpression reversing SAA1 KD) establishes pathway placement, single lab","pmids":["33719002"],"is_preprint":false},{"year":2021,"finding":"A T>C mutation in the SAA1 promoter (chr11:18287683) doubles basal SAA1 promoter activity and causes hereditary amyloid A amyloidosis with autosomal dominant inheritance; the mutation is linked to the amyloidogenic SAA1.1 haplotype, and tocilizumab (anti-IL-6 receptor antibody) has beneficial effects when given early.","method":"SAA1 promoter activity assay (luciferase or equivalent), genetic linkage analysis (LOD score >5), SAA level measurement in genetically affected and unaffected family members, amyloid composition analysis","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — functional promoter activity assay plus genetic linkage with LOD >5, amyloid composition confirmed as SAA1.1, in a characterized family","pmids":["34560138"],"is_preprint":false},{"year":2021,"finding":"SAA1 is upregulated in gastric cancer-associated fibroblasts (CAFs) due to increased H3K27ac (active enhancer mark) at the SAA1 promoter and two far upstream enhancer regions; BET bromodomain inhibitors (JQ1 and mivebresib) decrease SAA1 expression and tumor-promoting effects; conditioned medium from SAA1-overexpressing NCAFs increases gastric cancer cell migration comparably to CAF-CM, and CAF-CM tumor promotion is mostly abolished by SAA1 knockdown.","method":"ChIP-qPCR for H3K27ac, SAA1 overexpression in NCAFs, SAA1 knockdown in CAFs, conditioned medium migration assay, BET inhibitor treatment","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR establishes enhancer mechanism, gain- and loss-of-function migration assays with conditioned medium, single lab","pmids":["33284950"],"is_preprint":false},{"year":2022,"finding":"Ovarian granulosa cells produce SAA1, which can induce its own expression (feedforward loop); excessive SAA1 attenuates insulin-stimulated GLUT4 membrane translocation and glucose uptake via induction of PTEN and subsequent inhibition of Akt phosphorylation, effects blocked by TLR2/4 and NF-κB inhibitors.","method":"Primary granulosa cell culture, SAA1 treatment, GLUT4 membrane translocation assay, glucose uptake assay, western blot for PTEN and phospho-Akt, TLR2/4 and NF-κB inhibitor blocking experiments","journal":"Reproductive biology and endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway from SAA1 to TLR2/4-NF-κB-PTEN-Akt-GLUT4 established with inhibitors, single lab","pmids":["34980155"],"is_preprint":false},{"year":2023,"finding":"SAA1 promotes cancer stem cell transformation and drives type 2 immunity (Th2 polarization) via the P2X7 receptor, restricting anti-tumor immunity and promoting tumor fibrosis; anti-SAA neutralization antibody reverses these effects in patient-derived organoid/PBMC co-culture model.","method":"scRNA-seq (public dataset), ex vivo patient-derived organoid/PBMC co-culture, anti-SAA neutralizing antibody, P2X7 receptor inhibition, immune cell polarization assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — P2X7 dependence demonstrated with inhibition, neutralizing antibody rescue, patient-derived model, single lab","pmids":["37925492"],"is_preprint":false},{"year":2024,"finding":"Circadian clock BMAL1 suppresses SAA1 transcription in myeloid cells via the Rev-erbα-C/EBPβ axis: Rev-erbα (reduced in Bmal1-deficient cells) inhibits C/EBPβ binding to the Saa1 promoter; Bmal1 deficiency enhances C/EBPβ-Saa1 promoter binding and SAA1 expression; SAA1 in turn promotes noncanonical inflammasome-mediated pyroptosis; type 1 IFN receptor signaling is required for IFN-β/poly(I:C)-induced SAA1 production.","method":"Myeloid-specific Bmal1 knockout mice, transcriptome analysis, ChIP for C/EBPβ at Saa1 promoter, Rev-erbα inhibitor (SR8278), exogenous SAA1 administration, noncanonical inflammasome pyroptosis assays","journal":"Experimental & molecular medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP directly shows C/EBPβ promoter occupancy, genetic KO and pharmacological inhibition of Rev-erbα confirm pathway, type 1 IFN receptor requirement established, multiple orthogonal methods in one study","pmids":["38297162"],"is_preprint":false}],"current_model":"SAA1 is a liver-derived (and extrahepatic) acute-phase apolipoprotein that circulates primarily bound to HDL3 via ApoA-I and ApoA-II; its lipidation state critically determines bioactivity—lipid-free SAA1 signals through receptors including FPR2, CD36, SR-BII, and TLR2 to activate JNK/ERK/p38 MAPK and NF-κB pathways driving pro-inflammatory cytokine production, leukocyte chemotaxis (synergizing with CXCL8 and CCL3), macrophage differentiation (via CSF-1R), platelet activation, hepatic stellate cell migration (via PI3K/Rac/MLC), and insulin resistance (via PTEN/Akt inhibition), whereas HDL-associated SAA1 lacks most of these activities; SAA1 transcription is induced by IL-1/cytokines, STAT3, and C/EBPβ (regulated by the circadian clock via Rev-erbα-BMAL1), and is suppressed by glucocorticoid receptor-dependent mechanisms in a tissue-specific manner; the SAA1.1 isoform is selectively amyloidogenic and fibril-forming in vitro and in vivo, a property exploited by mast cell tryptase to generate amyloidogenic N-terminal fragments, while isoforms SAA1.1 and SAA1.3 additionally suppress angiogenesis through αVβ3 integrin binding."},"narrative":{"mechanistic_narrative":"SAA1 is an acute-phase apolipoprotein that circulates bound to high-density lipoprotein HDL3, where it associates with ApoA-I and ApoA-II and remodels HDL toward larger, phospholipid-depleted, triglyceride-enriched particles [PMID:198813, PMID:4086942, PMID:10845870, PMID:27105909]. Its hepatic synthesis is directly induced by the cytokine IL-1 and is secreted through the classical secretory pathway, while the gene family shows tissue-specific expression with distinct hepatic versus macrophage compartments [PMID:6807176, PMID:3680951]. SAA1 bioactivity is governed by its lipidation state: lipid-free SAA1 engages cell-surface receptors to drive pro-inflammatory signaling, whereas HDL association neutralizes or counter-regulates most of these effects [PMID:20075072, PMID:23165195, PMID:27898742]. The scavenger receptors CD36 and SR-BII mediate SAA1 uptake and trigger JNK, ERK1/2, and p38 MAPK signaling with downstream cytokine/chemokine output, and SAA1 also signals through TLR2 to recruit and activate hepatic stellate cells (via PI3K/Rac/MLC phosphorylation), platelets, and to impair insulin signaling through NF-κB-dependent mechanisms [PMID:20075072, PMID:28423002, PMID:34113824, PMID:33813276, PMID:31060494]. A rigorous re-purification study established that much of the cytokine-inducing, ROS-generating, and macrophage-differentiating activity attributed to recombinant SAA1 reflected bacterial contaminants, while genuine SAA1 retains FPR2-dependent leukocyte recruitment and synergy with chemokines such as CXCL8 and CCL3 — an activity mediated by intact protein rather than C-terminal fragments [PMID:32477346, PMID:29371208]. Distinct from its inflammatory signaling, the SAA1.1 isoform is intrinsically fibrillogenic and amyloidogenic in vitro and in vivo, and mast cell tryptase cleaves SAA1 to release a highly amyloidogenic N-terminal fragment, defining SAA1 as the precursor of AA amyloidosis; a promoter mutation that doubles SAA1 expression causes autosomal dominant hereditary amyloid A amyloidosis [PMID:11140693, PMID:16483749, PMID:34560138]. SAA1 transcription is controlled combinatorially by STAT3, glucocorticoid receptor (in a tissue-specific manner), enhancer acetylation, and the circadian Rev-erbα–C/EBPβ axis downstream of BMAL1 [PMID:12938239, PMID:34597680, PMID:33284950, PMID:38297162]. Isoform-specific functions extend to angiogenesis suppression, where SAA1.1 and SAA1.3 (but not SAA1.5) bind αVβ3 integrin to block endothelial adhesion and induce apoptosis [PMID:24608426].","teleology":[{"year":1977,"claim":"Established the fundamental biochemical identity of SAA as an HDL-associated apolipoprotein rather than a free serum protein, defining the lipoprotein context for all later function.","evidence":"Ultracentrifugation and density gradient fractionation of human serum with immunochemical analysis","pmids":["198813","301900"],"confidence":"High","gaps":["Did not resolve which HDL apolipoproteins SAA contacts directly","No functional consequence of HDL binding established"]},{"year":1982,"claim":"Identified the liver as a direct cytokine target for SAA induction, explaining the acute-phase rise in SAA during inflammation.","evidence":"In vitro mouse hepatocyte culture with purified leukocytic pyrogen (IL-1), immunoprecipitation, and cell-free translation","pmids":["6807176"],"confidence":"Medium","gaps":["Did not define transcription factors transducing the IL-1 signal","Single inducer tested"]},{"year":1985,"claim":"Showed SAA enrichment causally remodels HDL particle composition and size, demonstrating that SAA is not a passive passenger but alters lipoprotein structure.","evidence":"Biophysical fractionation plus in vitro HDL-SAA reconstitution","pmids":["4086942"],"confidence":"High","gaps":["Functional consequence of altered HDL for inflammation or lipid transport not tested"]},{"year":1987,"claim":"Revealed tissue-specific and isoform-specific expression of the SAA gene family, distinguishing hepatic SAA1/SAA2 from macrophage SAA3 and linking expression shifts to amyloidosis.","evidence":"Comparative mRNA expression across mouse tissues in acute-phase and amyloidosis models","pmids":["3680951"],"confidence":"Medium","gaps":["mRNA-level only","Does not address human SAA1 isoform specifics"]},{"year":1993,"claim":"Defined SAA1 protein polymorphisms and common N-terminal post-translational processing, providing the molecular basis for later isoform-specific functional differences.","evidence":"Multiple orthogonal mass spectrometry methods and amino acid analysis","pmids":["8512321"],"confidence":"High","gaps":["Functional consequences of the polymorphisms not addressed","No link to amyloidogenicity at this stage"]},{"year":2000,"claim":"Demonstrated that amyloidogenicity is an intrinsic structural property of the SAA1.1 isoform, separating fibril-forming from non-fibril-forming SAA variants.","evidence":"Recombinant fibril formation assays plus adenoviral in vivo expression and amyloid induction in mice","pmids":["11140693","10845870"],"confidence":"High","gaps":["Did not identify cellular proteases or cofactors that initiate fibrillogenesis in vivo","Mechanism distinguishing fibril-prone from resistant isoforms structurally undefined"]},{"year":2006,"claim":"Linked mast cell biology to amyloidosis by showing tryptase cleaves SAA into an amyloidogenic N-terminal fragment, defining a proteolytic route to fibril precursors.","evidence":"HMC-1 mast cell culture, protease cleavage assays, LC-MS fragment identification, and electron microscopy of protofibrils","pmids":["16483749"],"confidence":"High","gaps":["In vivo relevance of mast-cell-generated fragments to human amyloidosis not established","Cytokine readouts may reflect impure preparations"]},{"year":2010,"claim":"Identified CD36 as a functional SAA receptor coupling SAA uptake to JNK/ERK MAPK-driven cytokine production, and showed HDL association neutralizes signaling.","evidence":"CD36 overexpression and knockout cells, uptake and cytokine assays, MAPK phosphorylation, and blocking peptides","pmids":["20075072"],"confidence":"High","gaps":["Cytokine effects later complicated by contaminant concerns in rSAA","Relative contribution of CD36 versus other receptors in vivo unresolved"]},{"year":2012,"claim":"Established that lipidation state determines SAA signaling, with lipid-poor but not HDL-bound SAA activating TLR2, while questioning the in vivo physiological cytokine role.","evidence":"J774 macrophage stimulation with lipid-poor versus HDL-associated SAA, TLR2 neutralizing antibodies, and adenoviral expression in SAA-deficient mice","pmids":["23165195"],"confidence":"Medium","gaps":["In vivo cytokine induction not reproduced","Did not exclude preparation contaminants"]},{"year":2014,"claim":"Defined two non-redundant SAA1 activities: receptor-driven macrophage differentiation downstream of CSF-1R/FPR2, and isoform-specific anti-angiogenesis via αVβ3 integrin binding.","evidence":"Monocyte differentiation with FPR2 and CSF-1R inhibitors plus airway model; isoform restoration in NPC cells with integrin binding and endothelial apoptosis assays","pmids":["24846388","24608426"],"confidence":"Medium","gaps":["Macrophage differentiation activity later attributed partly to contaminants","Structural basis of isoform-selective integrin binding undefined"]},{"year":2016,"claim":"Mapped HDL counter-regulation of SAA inflammatory signaling and resolved the structural proximity of SAA to ApoA-I on the HDL surface.","evidence":"Macrophage HDL counter-regulation assays with TLR4 dependence; chemical crosslinking mass spectrometry of HDL-SAA particles","pmids":["27898742","27105909"],"confidence":"Medium","gaps":["Mechanism by which HDL physically blocks receptor engagement not resolved","Crosslinking provides proximity but not a high-resolution structure"]},{"year":2017,"claim":"Identified SR-BII as a second scavenger-receptor route for SAA uptake and tri-MAPK activation, corroborated by transgenic in vivo inflammatory responses.","evidence":"SR-BII overexpression cells with uptake/cytokine/MAPK assays and hSR-BII transgenic mouse SAA challenge","pmids":["28423002"],"confidence":"High","gaps":["Relative in vivo contribution of SR-BII versus CD36 and TLR2 unresolved","Did not address lipidation-state dependence"]},{"year":2018,"claim":"Showed that the leukocyte-recruiting function of SAA1 operates chiefly by FPR2-dependent synergy with chemokines, and that C-terminal fragments cannot act alone.","evidence":"Purified natural and synthetic SAA1 fragments, chemotaxis assays, FPR2 desensitization and antagonist blocking, and in vivo neutrophil recruitment","pmids":["29371208"],"confidence":"High","gaps":["Endogenous source of the synergizing fragments in vivo not defined","Does not address direct receptor structural engagement"]},{"year":2020,"claim":"Resolved long-standing contradictions by demonstrating that purified contaminant-free SAA1 retains FPR2-mediated chemotaxis but lacks most TLR-attributed cytokine, ROS, MMP-9, and differentiation activities, reframing the field's interpretation of SAA1 function.","evidence":"RP-HPLC-purified endotoxin-free rSAA1 across chemotaxis, cytokine, ROS, MMP-9, differentiation, and in vivo recruitment assays","pmids":["32477346"],"confidence":"High","gaps":["Does not exclude that endogenous SAA1 modifications confer additional activities","Receptor specificity for surviving activities partially defined"]},{"year":2021,"claim":"Expanded SAA1 into a tissue-remodeling and metabolic effector, signaling via TLR2 to drive hepatic stellate cell migration, platelet aggregation, and insulin resistance, with promoter mutation establishing a direct Mendelian amyloidosis link.","evidence":"TLR2 genetic/pharmacological epistasis with MLC and Rac readouts; platelet aggregation assays; SAA1 silencing in HFD mice; STAT3 ChIP and VIMP co-IP; promoter luciferase plus family linkage (LOD>5)","pmids":["34113824","33813276","31060494","31216990","34597680","34560138","33719002","33284950"],"confidence":"High","gaps":["Multiple downstream pathways shown in distinct single-lab disease models","Whether lipidation state modulates these effects often untested"]},{"year":2022,"claim":"Detailed a receptor-to-metabolism cascade in which SAA1 induces PTEN to inhibit Akt and impair GLUT4-dependent glucose uptake through TLR2/4-NF-κB signaling, with feedforward self-induction.","evidence":"Granulosa cell culture, GLUT4 translocation and glucose uptake assays, PTEN/phospho-Akt western blots, and TLR/NF-κB inhibitor blocking","pmids":["34980155"],"confidence":"Medium","gaps":["Single cell type and lab","In vivo metabolic relevance not established here"]},{"year":2024,"claim":"Placed SAA1 under circadian control by showing BMAL1 represses SAA1 via the Rev-erbα–C/EBPβ axis, coupling rhythmic transcription to SAA1-driven inflammasome pyroptosis.","evidence":"Myeloid Bmal1 knockout mice, C/EBPβ ChIP at the Saa1 promoter, Rev-erbα inhibition, and pyroptosis assays","pmids":["38297162"],"confidence":"High","gaps":["Human relevance of myeloid circadian SAA1 regulation untested","Receptor mediating pyroptotic SAA1 action not pinned down"]},{"year":null,"claim":"It remains unresolved how the multiple candidate receptors (FPR2, CD36, SR-BII, TLR2, P2X7, αVβ3) are selected in vivo, and how lipidation state, isoform identity, and proteolytic processing jointly dictate which SAA1 activity dominates in a given tissue.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unified structural model of SAA1-receptor engagement","Physiological versus contaminant-driven activities not fully partitioned in vivo","Relative receptor usage across tissues undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,3,8,16]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[11,17,18,23]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[7,10]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[11,17]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,2,3]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11,17,18,21]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[2,31]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,10,27]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,23,29]}],"complexes":["HDL (HDL3)"],"partners":["APOA1","APOA2","CD36","SCARB1","TLR2","FPR2","ITGAV/ITGB3","VIMP (SELENOS)"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P0DJI8","full_name":"Serum amyloid A-1 protein","aliases":[],"length_aa":122,"mass_kda":13.5,"function":"Major acute phase protein","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P0DJI8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SAA1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":5,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SAA1","total_profiled":1310},"omim":[{"mim_id":"608107","title":"MEFV INNATE IMMUNITY REGULATOR, PYRIN; MEFV","url":"https://www.omim.org/entry/608107"},{"mim_id":"601979","title":"AUTOINFLAMMATORY SYNDROME WITH CYTOPENIA, HYPERZINCEMIA, AND HYPERCALPROTECTINEMIA; AICZC","url":"https://www.omim.org/entry/601979"},{"mim_id":"107650","title":"APNEA, OBSTRUCTIVE SLEEP","url":"https://www.omim.org/entry/107650"},{"mim_id":"104752","title":"SERUM AMYLOID A4; SAA4","url":"https://www.omim.org/entry/104752"},{"mim_id":"104751","title":"SERUM AMYLOID A2; SAA2","url":"https://www.omim.org/entry/104751"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":54032.7}],"url":"https://www.proteinatlas.org/search/SAA1"},"hgnc":{"alias_symbol":["PIG4","TP53I4"],"prev_symbol":["SAA"]},"alphafold":{"accession":"P0DJI8","domains":[{"cath_id":"1.10.132.110","chopping":"20-114","consensus_level":"high","plddt":96.8123,"start":20,"end":114}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P0DJI8","model_url":"https://alphafold.ebi.ac.uk/files/AF-P0DJI8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P0DJI8-F1-predicted_aligned_error_v6.png","plddt_mean":93.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SAA1","jax_strain_url":"https://www.jax.org/strain/search?query=SAA1"},"sequence":{"accession":"P0DJI8","fasta_url":"https://rest.uniprot.org/uniprotkb/P0DJI8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P0DJI8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P0DJI8"}},"corpus_meta":[{"pmid":"198813","id":"PMC_198813","title":"Amyloid protein SAA is associated with high density lipoprotein from human serum.","date":"1977","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/198813","citation_count":384,"is_preprint":false},{"pmid":"8817153","id":"PMC_8817153","title":"Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice.","date":"1996","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/8817153","citation_count":296,"is_preprint":false},{"pmid":"27087246","id":"PMC_27087246","title":"Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults.","date":"2016","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27087246","citation_count":192,"is_preprint":false},{"pmid":"7504491","id":"PMC_7504491","title":"Serum amyloid A (SAA): an acute phase protein and apolipoprotein.","date":"1993","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/7504491","citation_count":169,"is_preprint":false},{"pmid":"10369107","id":"PMC_10369107","title":"Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness.","date":"1999","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10369107","citation_count":151,"is_preprint":false},{"pmid":"12687559","id":"PMC_12687559","title":"The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever.","date":"2003","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/12687559","citation_count":138,"is_preprint":false},{"pmid":"32189310","id":"PMC_32189310","title":"Serum Amyloid A (SAA) Proteins.","date":"2020","source":"Sub-cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32189310","citation_count":122,"is_preprint":false},{"pmid":"52891","id":"PMC_52891","title":"Isolation and characterization of amyloid-related serum protein SAA as a low molecular weight protein.","date":"1975","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/52891","citation_count":120,"is_preprint":false},{"pmid":"21141971","id":"PMC_21141971","title":"Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer.","date":"2011","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/21141971","citation_count":110,"is_preprint":false},{"pmid":"4086942","id":"PMC_4086942","title":"Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction.","date":"1985","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/4086942","citation_count":104,"is_preprint":false},{"pmid":"6807176","id":"PMC_6807176","title":"The biology of SAA: identification of the inducer, in vitro synthesis, and heterogeneity demonstrated with monoclonal antibodies.","date":"1982","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/6807176","citation_count":99,"is_preprint":false},{"pmid":"32535957","id":"PMC_32535957","title":"Cancer-associated adipocytes promote pancreatic cancer progression through SAA1 expression.","date":"2020","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/32535957","citation_count":89,"is_preprint":false},{"pmid":"20075072","id":"PMC_20075072","title":"CD36 is a novel serum amyloid A (SAA) receptor mediating SAA binding and SAA-induced signaling in human and rodent cells.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20075072","citation_count":89,"is_preprint":false},{"pmid":"33447953","id":"PMC_33447953","title":"High-Density Lipoproteins and Serum Amyloid A (SAA).","date":"2021","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/33447953","citation_count":82,"is_preprint":false},{"pmid":"21103356","id":"PMC_21103356","title":"Polymorphisms in the SAA1/2 gene are associated with carotid intima media thickness in healthy Han Chinese subjects: the Cardiovascular Risk Survey.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21103356","citation_count":73,"is_preprint":false},{"pmid":"2607146","id":"PMC_2607146","title":"Direct binding enzyme-linked immunosorbent assay (ELISA) for serum amyloid A (SAA).","date":"1989","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/2607146","citation_count":66,"is_preprint":false},{"pmid":"22771314","id":"PMC_22771314","title":"SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors.","date":"2012","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/22771314","citation_count":64,"is_preprint":false},{"pmid":"10543406","id":"PMC_10543406","title":"Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis.","date":"1999","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10543406","citation_count":59,"is_preprint":false},{"pmid":"3015139","id":"PMC_3015139","title":"Localization of human SAA gene(s) to chromosome 11 and detection of DNA polymorphisms.","date":"1986","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/3015139","citation_count":57,"is_preprint":false},{"pmid":"31100086","id":"PMC_31100086","title":"Expression of SAA1, SAA2 and SAA4 genes in human primary monocytes and monocyte-derived macrophages.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31100086","citation_count":55,"is_preprint":false},{"pmid":"26177823","id":"PMC_26177823","title":"Quantification of SAA1 and SAA2 in lung cancer plasma using the isotype-specific PRM assays.","date":"2015","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/26177823","citation_count":52,"is_preprint":false},{"pmid":"15018633","id":"PMC_15018633","title":"Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects.","date":"2004","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15018633","citation_count":50,"is_preprint":false},{"pmid":"11341746","id":"PMC_11341746","title":"Serum amyloid A protein (SAA) in colorectal carcinoma.","date":"2001","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11341746","citation_count":49,"is_preprint":false},{"pmid":"24846388","id":"PMC_24846388","title":"SAA drives proinflammatory heterotypic macrophage differentiation in the lung via CSF-1R-dependent signaling.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24846388","citation_count":46,"is_preprint":false},{"pmid":"3680951","id":"PMC_3680951","title":"Differential expression of the amyloid SAA 3 gene in liver and peritoneal macrophages of mice undergoing dissimilar inflammatory episodes.","date":"1987","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3680951","citation_count":45,"is_preprint":false},{"pmid":"32477346","id":"PMC_32477346","title":"Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32477346","citation_count":44,"is_preprint":false},{"pmid":"12938239","id":"PMC_12938239","title":"Tissue-specific regulation of the human acute-phase serum amyloid A genes, SAA1 and SAA2, by glucocorticoids in hepatic and epithelial cells.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12938239","citation_count":44,"is_preprint":false},{"pmid":"23165195","id":"PMC_23165195","title":"SAA does not induce cytokine production in physiological conditions.","date":"2012","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/23165195","citation_count":44,"is_preprint":false},{"pmid":"11156544","id":"PMC_11156544","title":"Relative serum amyloid A (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis.","date":"2001","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/11156544","citation_count":42,"is_preprint":false},{"pmid":"19536090","id":"PMC_19536090","title":"Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.","date":"2009","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19536090","citation_count":39,"is_preprint":false},{"pmid":"32190704","id":"PMC_32190704","title":"Urinary I-FABP, L-FABP, TFF-3, and SAA Can Diagnose and Predict the Disease Course in Necrotizing Enterocolitis at the Early Stage of Disease.","date":"2020","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/32190704","citation_count":39,"is_preprint":false},{"pmid":"23704321","id":"PMC_23704321","title":"Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria.","date":"2013","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23704321","citation_count":39,"is_preprint":false},{"pmid":"14696796","id":"PMC_14696796","title":"Analysis of the modifying effects of SAA1, SAA2 and TNF-alpha gene polymorphisms on development of amyloidosis in FMF patients.","date":"2003","source":"The Turkish journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/14696796","citation_count":38,"is_preprint":false},{"pmid":"33813276","id":"PMC_33813276","title":"Hepatocytes derived increased SAA1 promotes intrahepatic platelet aggregation and aggravates liver inflammation in NAFLD.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33813276","citation_count":37,"is_preprint":false},{"pmid":"33626219","id":"PMC_33626219","title":"Arecoline induces epithelial-mesenchymal transformation and promotes metastasis of oral cancer by SAA1 expression.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/33626219","citation_count":36,"is_preprint":false},{"pmid":"22230385","id":"PMC_22230385","title":"Widespread expression of SAA and Hp RNA in bovine tissues after evaluation of suitable reference genes.","date":"2011","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/22230385","citation_count":34,"is_preprint":false},{"pmid":"21449704","id":"PMC_21449704","title":"Polymorphisms in the SAA1 gene are associated with ankle-to-brachial index in Han Chinese healthy subjects.","date":"2011","source":"Blood pressure","url":"https://pubmed.ncbi.nlm.nih.gov/21449704","citation_count":34,"is_preprint":false},{"pmid":"15170927","id":"PMC_15170927","title":"Influence of Serum Amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/C-reactive protein values in patients with familial mediterranean fever in the Turkish population.","date":"2004","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/15170927","citation_count":32,"is_preprint":false},{"pmid":"33284950","id":"PMC_33284950","title":"SAA1 is upregulated in gastric cancer-associated fibroblasts possibly by its enhancer activation.","date":"2021","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/33284950","citation_count":30,"is_preprint":false},{"pmid":"24146912","id":"PMC_24146912","title":"Organization and biology of the porcine serum amyloid A (SAA) gene cluster: isoform specific responses to bacterial infection.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24146912","citation_count":30,"is_preprint":false},{"pmid":"34729020","id":"PMC_34729020","title":"The Clinical Diagnostic Values of SAA, PCT, CRP, and IL-6 in Children with Bacterial, Viral, or Co-Infections.","date":"2021","source":"International journal of general medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34729020","citation_count":30,"is_preprint":false},{"pmid":"31216990","id":"PMC_31216990","title":"SAA1 increases NOX4/ROS production to promote LPS-induced inflammation in vascular smooth muscle cells through activating p38MAPK/NF-κB pathway.","date":"2019","source":"BMC molecular and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31216990","citation_count":28,"is_preprint":false},{"pmid":"31060494","id":"PMC_31060494","title":"Silencing of SAA1 inhibits palmitate- or high-fat diet induced insulin resistance through suppression of the NF-κB pathway.","date":"2019","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/31060494","citation_count":27,"is_preprint":false},{"pmid":"37925492","id":"PMC_37925492","title":"SAA suppresses α-PD-1 induced anti-tumor immunity by driving TH2 polarization in lung adenocarcinoma.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37925492","citation_count":26,"is_preprint":false},{"pmid":"31231209","id":"PMC_31231209","title":"Apoproteins E, A-I, and SAA in Macrophage Pathobiology Related to Atherogenesis.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31231209","citation_count":25,"is_preprint":false},{"pmid":"301900","id":"PMC_301900","title":"Serum amyloid A (SAA) protein-interaction with itself and serum albumin.","date":"1977","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/301900","citation_count":25,"is_preprint":false},{"pmid":"34084746","id":"PMC_34084746","title":"High SAA1 Expression Predicts Advanced Tumors in Renal Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34084746","citation_count":24,"is_preprint":false},{"pmid":"24608426","id":"PMC_24608426","title":"SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24608426","citation_count":24,"is_preprint":false},{"pmid":"29371208","id":"PMC_29371208","title":"COOH-terminal SAA1 peptides fail to induce chemokines but synergize with CXCL8 and CCL3 to recruit leukocytes via FPR2.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29371208","citation_count":24,"is_preprint":false},{"pmid":"16483749","id":"PMC_16483749","title":"Serum amyloid A (SAA) activates human mast cells which leads into degradation of SAA and generation of an amyloidogenic SAA fragment.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16483749","citation_count":24,"is_preprint":false},{"pmid":"3095915","id":"PMC_3095915","title":"Serum amyloid protein A (SAA): an indicator of inflammation in AIDS and AIDS-related complex (ARC).","date":"1986","source":"Scandinavian journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/3095915","citation_count":24,"is_preprint":false},{"pmid":"17039310","id":"PMC_17039310","title":"SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis.","date":"2006","source":"Modern rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/17039310","citation_count":23,"is_preprint":false},{"pmid":"10845870","id":"PMC_10845870","title":"Expression of mouse acute-phase (SAA1.1) and constitutive (SAA4) serum amyloid A isotypes: influence on lipoprotein profiles.","date":"2000","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10845870","citation_count":23,"is_preprint":false},{"pmid":"33215460","id":"PMC_33215460","title":"Expressions of SAA, CRP, and FERR in different severities of COVID-19.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33215460","citation_count":23,"is_preprint":false},{"pmid":"16171978","id":"PMC_16171978","title":"Distribution of saa gene variants in verocytotoxigenic Escherichia coli isolated from cattle and food.","date":"2005","source":"Research in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/16171978","citation_count":23,"is_preprint":false},{"pmid":"21439655","id":"PMC_21439655","title":"Serum amyloid A3 (SAA3), not SAA1 appears to be the major acute phase SAA isoform in the pig.","date":"2011","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/21439655","citation_count":23,"is_preprint":false},{"pmid":"23437051","id":"PMC_23437051","title":"The contribution of SAA1 polymorphisms to Familial Mediterranean fever susceptibility in the Japanese population.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23437051","citation_count":22,"is_preprint":false},{"pmid":"27898742","id":"PMC_27898742","title":"High-Density Lipoprotein (HDL) Counter-Regulates Serum Amyloid A (SAA)-Induced sPLA2-IIE and sPLA2-V Expression in Macrophages.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27898742","citation_count":22,"is_preprint":false},{"pmid":"33161846","id":"PMC_33161846","title":"SAA (Serum Amyloid A): A Novel Predictor of Stroke-Associated Infections.","date":"2020","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/33161846","citation_count":21,"is_preprint":false},{"pmid":"34560138","id":"PMC_34560138","title":"A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis.","date":"2021","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/34560138","citation_count":20,"is_preprint":false},{"pmid":"11140693","id":"PMC_11140693","title":"Expression of mouse apolipoprotein SAA1.1 in CE/J mice: isoform-specific effects on amyloidogenesis.","date":"2000","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11140693","citation_count":20,"is_preprint":false},{"pmid":"7253566","id":"PMC_7253566","title":"Enzyme-linked immunosorbent assay of serum protein SAA in rhesus monkeys with secondary amyloidosis.","date":"1981","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7253566","citation_count":20,"is_preprint":false},{"pmid":"8512321","id":"PMC_8512321","title":"A novel polymorphism of human serum amyloid A protein, SAA1 gamma, is characterized by alanines at both residues 52 and 57.","date":"1993","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/8512321","citation_count":20,"is_preprint":false},{"pmid":"37717911","id":"PMC_37717911","title":"Enteric fungi protect against intestinal ischemia-reperfusion injury via inhibiting the SAA1-GSDMD pathway.","date":"2023","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/37717911","citation_count":19,"is_preprint":false},{"pmid":"32582166","id":"PMC_32582166","title":"De novo Synthesis of SAA1 in the Placenta Participates in Parturition.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32582166","citation_count":19,"is_preprint":false},{"pmid":"34052408","id":"PMC_34052408","title":"SAA and CRP are potential indicators in distinction and severity assessment for children with influenza.","date":"2021","source":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","url":"https://pubmed.ncbi.nlm.nih.gov/34052408","citation_count":19,"is_preprint":false},{"pmid":"34597680","id":"PMC_34597680","title":"SAA1 is transcriptionally activated by STAT3 and accelerates renal interstitial fibrosis by inducing endoplasmic reticulum stress.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34597680","citation_count":19,"is_preprint":false},{"pmid":"36173129","id":"PMC_36173129","title":"Mouse Bone Marrow Mesenchymal Stem Cells Inhibit Sepsis-Induced Lung Injury in Mice via Exosomal SAA1.","date":"2022","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/36173129","citation_count":19,"is_preprint":false},{"pmid":"28423002","id":"PMC_28423002","title":"Human SR-BII mediates SAA uptake and contributes to SAA pro-inflammatory signaling in vitro and in vivo.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28423002","citation_count":19,"is_preprint":false},{"pmid":"3931569","id":"PMC_3931569","title":"Serum amyloid A protein (SAA) subtypes in acute and chronic inflammatory conditions.","date":"1985","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/3931569","citation_count":19,"is_preprint":false},{"pmid":"36817589","id":"PMC_36817589","title":"Acute-serum amyloid A and A-SAA-derived peptides as formyl peptide receptor (FPR) 2 ligands.","date":"2023","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36817589","citation_count":18,"is_preprint":false},{"pmid":"3984747","id":"PMC_3984747","title":"Amyloid-related serum protein (SAA) during and after pregnancy in healthy women and women with rheumatic disease.","date":"1985","source":"Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/3984747","citation_count":17,"is_preprint":false},{"pmid":"33854635","id":"PMC_33854635","title":"SAA1 knockdown promotes the apoptosis of glioblastoma cells via downregulation of AKT signaling.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33854635","citation_count":16,"is_preprint":false},{"pmid":"9428637","id":"PMC_9428637","title":"Serum amyloid A (SAA) protein enhances formation of cyclooxygenase metabolites of activated human monocytes.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9428637","citation_count":16,"is_preprint":false},{"pmid":"30544414","id":"PMC_30544414","title":"Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still's disease.","date":"2018","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30544414","citation_count":15,"is_preprint":false},{"pmid":"38297162","id":"PMC_38297162","title":"Deficiency of circadian clock gene Bmal1 exacerbates noncanonical inflammasome-mediated pyroptosis and lethality via Rev-erbα-C/EBPβ-SAA1 axis.","date":"2024","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38297162","citation_count":14,"is_preprint":false},{"pmid":"10487231","id":"PMC_10487231","title":"Expression of recombinant feline serum amyloid A (SAA) protein.","date":"1999","source":"The Journal of veterinary medical science","url":"https://pubmed.ncbi.nlm.nih.gov/10487231","citation_count":14,"is_preprint":false},{"pmid":"34113824","id":"PMC_34113824","title":"SAA1/TLR2 axis directs chemotactic migration of hepatic stellate cells responding to injury.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34113824","citation_count":14,"is_preprint":false},{"pmid":"572349","id":"PMC_572349","title":"Serum amyloid protein SAA, C-reactive protein and lysozyme in leprosy.","date":"1979","source":"International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association","url":"https://pubmed.ncbi.nlm.nih.gov/572349","citation_count":14,"is_preprint":false},{"pmid":"32695227","id":"PMC_32695227","title":"MFGE8, ALB, APOB, APOE, SAA1, A2M, and C3 as Novel Biomarkers for Stress Cardiomyopathy.","date":"2020","source":"Cardiovascular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/32695227","citation_count":13,"is_preprint":false},{"pmid":"37357772","id":"PMC_37357772","title":"HDL anti-inflammatory function is impaired and associated with high SAA1 and low APOA4 levels in aneurysmal subarachnoid hemorrhage.","date":"2023","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37357772","citation_count":13,"is_preprint":false},{"pmid":"11207541","id":"PMC_11207541","title":"CpG-DNA upregulates the major acute-phase proteins SAA and SAP.","date":"1999","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/11207541","citation_count":13,"is_preprint":false},{"pmid":"32921632","id":"PMC_32921632","title":"LINC00160 mediates sunitinib resistance in renal cell carcinoma via SAA1 that is implicated in STAT3 activation and compound transportation.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32921632","citation_count":13,"is_preprint":false},{"pmid":"34087538","id":"PMC_34087538","title":"Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.","date":"2021","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/34087538","citation_count":13,"is_preprint":false},{"pmid":"33719002","id":"PMC_33719002","title":"SAA1 regulates pro-labour mediators in term labour by activating YAP pathway.","date":"2021","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33719002","citation_count":12,"is_preprint":false},{"pmid":"35757752","id":"PMC_35757752","title":"Serum Proteomic Analysis Identifies SAA1, FGA, SAP, and CETP as New Biomarkers for Eosinophilic Granulomatosis With Polyangiitis.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35757752","citation_count":12,"is_preprint":false},{"pmid":"27105909","id":"PMC_27105909","title":"Heparin interactions with apoA1 and SAA in inflammation-associated HDL.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27105909","citation_count":12,"is_preprint":false},{"pmid":"34980155","id":"PMC_34980155","title":"Elevated SAA1 promotes the development of insulin resistance in ovarian granulosa cells in polycystic ovary syndrome.","date":"2022","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/34980155","citation_count":12,"is_preprint":false},{"pmid":"32797788","id":"PMC_32797788","title":"Serum Amyloid A (SAA) Concentration after Vaccination in Horses and Mules.","date":"2020","source":"Journal of equine veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/32797788","citation_count":12,"is_preprint":false},{"pmid":"29870759","id":"PMC_29870759","title":"The ectoenzyme-side of matrix metalloproteinases (MMPs) makes inflammation by serum amyloid A (SAA) and chemokines go round.","date":"2018","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29870759","citation_count":12,"is_preprint":false},{"pmid":"37022639","id":"PMC_37022639","title":"SAA1 deficiency alleviates cardiac remodeling by inhibiting NF-κB/p38/JNK and TGFβ/Smad pathways.","date":"2023","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/37022639","citation_count":11,"is_preprint":false},{"pmid":"29511620","id":"PMC_29511620","title":"Serum amyloid A1 (SAA1) protein in human colostrum.","date":"2018","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/29511620","citation_count":11,"is_preprint":false},{"pmid":"1764061","id":"PMC_1764061","title":"Characterization of an isoelectric focusing variant of SAA1 (ASP-72) in a family of Turkish origin.","date":"1991","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/1764061","citation_count":11,"is_preprint":false},{"pmid":"38289016","id":"PMC_38289016","title":"SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness.","date":"2024","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38289016","citation_count":10,"is_preprint":false},{"pmid":"23522429","id":"PMC_23522429","title":"Associations of SAA1 gene polymorphism with lipid lelvels and osteoporosis in Chinese women.","date":"2013","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/23522429","citation_count":10,"is_preprint":false},{"pmid":"39557828","id":"PMC_39557828","title":"Sodium oligomannate disrupts the adherence of Ribhigh bacteria to gut epithelia to block SAA-triggered Th1 inflammation in 5XFAD transgenic mice.","date":"2024","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/39557828","citation_count":10,"is_preprint":false},{"pmid":"2309099","id":"PMC_2309099","title":"apo-SAA1/apo-SAA2 isotype ratios during casein- and amyloid-enhancing-factor-induced secondary amyloidosis in A/J and C57BL/6J mice mice.","date":"1990","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2309099","citation_count":10,"is_preprint":false},{"pmid":"27313400","id":"PMC_27313400","title":"CRP and SAA1 Haplotypes Are Associated with Both C-Reactive Protein and Serum Amyloid A Levels: Role of Suppression Effects.","date":"2016","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/27313400","citation_count":9,"is_preprint":false},{"pmid":"37707574","id":"PMC_37707574","title":"Identification of SAA1 as a novel metastasis marker in ovarian cancer and development of a graphene-based detection platform for early assessment.","date":"2023","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37707574","citation_count":9,"is_preprint":false},{"pmid":"33688224","id":"PMC_33688224","title":"Relationship Between Serum Amyloid A1 (SAA1) Gene Polymorphisms Studies with Obesity in the Saudi Population.","date":"2021","source":"Diabetes, metabolic syndrome and obesity : targets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33688224","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50475,"output_tokens":8995,"usd":0.143175,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19091,"output_tokens":5677,"usd":0.11869,"stage2_stop_reason":"end_turn"},"total_usd":0.261865,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1977,\n      \"finding\": \"SAA protein is physically associated with high density lipoprotein HDL3 in human serum, co-sedimenting at density 1.12–1.21 g/cm3 with apolipoproteins ApoA-I and ApoA-II, and can be dissociated into low molecular weight species (~13,000 Da) under dissociating conditions.\",\n      \"method\": \"Sequential ultracentrifugation, density gradient fractionation, immunochemical analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct physical fractionation with density gradients, replicated across multiple subsequent studies\",\n      \"pmids\": [\"198813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1977,\n      \"finding\": \"Low molecular weight SAA (~12,000 Da) self-aggregates and binds serum albumin but not IgG or Bence Jones proteins, forming ~85,000 Da and ~170,000 Da complexes under physiological conditions.\",\n      \"method\": \"Gel filtration with radiolabeled 125I-SAA, cold competition binding assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, direct binding experiment with radiolabeled protein, no replication cited\",\n      \"pmids\": [\"301900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1982,\n      \"finding\": \"SAA synthesis in isolated mouse hepatocytes is induced in vitro by purified leukocytic pyrogen (LP/IL-1), demonstrating the liver as the direct target for cytokine-driven SAA production; colchicine treatment blocks SAA secretion and causes intracellular accumulation, indicating secretory pathway dependence.\",\n      \"method\": \"In vitro hepatocyte culture, immunoprecipitation, autoradiography, wheat-germ cell-free translation of hepatic mRNA\",\n      \"journal\": \"Annals of the New York Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro reconstitution with purified inducer, multiple orthogonal readouts (secretion blockade, cell-free translation), single lab\",\n      \"pmids\": [\"6807176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"SAA enrichment of HDL particles (up to 87% of HDL apolipoprotein) is associated with phospholipid depletion, increased triglyceride content, and larger particle size (radius 4.5–5.3 nm) at normal HDL3 density; this size-density dissociation was also reproduced by in vitro incubation of normal HDL with SAA.\",\n      \"method\": \"Sequential ultracentrifugation, SDS-PAGE, gradient gel electrophoresis, in vitro HDL-SAA incubation\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal biophysical methods, in vitro reconstitution confirming causal role of SAA, replicated in vivo and in vitro in same study\",\n      \"pmids\": [\"4086942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Mouse peritoneal macrophages express the SAA3 gene exclusively (not SAA1 or SAA2), while liver co-expresses all three SAA genes; during accelerated amyloidosis, macrophage SAA3 expression increases as hepatic SAA1/SAA2 expression decreases, indicating distinct extrahepatic and tissue-specific regulation of SAA gene family members.\",\n      \"method\": \"Differential gene expression analysis (mRNA), comparative acute-phase induction models in mice\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple inflammatory models compared, tissue-specific mRNA expression with functional disease context, single lab\",\n      \"pmids\": [\"3680951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"SAA1 gamma isoform is characterized by alanines at both residues 52 and 57 (rather than valine at one position), representing a novel polymorphism; N-terminal des-Arg and des-Arg-Ser forms of all SAA1 subsets were identified, indicating common post-translational N-terminal processing.\",\n      \"method\": \"Ion-spray mass spectrometry, LC/fast atom bombardment mass spectrometry, collision-activated dissociation MS, amino acid analysis\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal mass spectrometry methods definitively characterizing protein sequence and PTM, single lab\",\n      \"pmids\": [\"8512321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"SAA1 (but not ApoA-I) enhances cyclooxygenase metabolite formation (TXA2, PGE2, PGF2α) in calcium ionophore-stimulated human monocytes in a dose-dependent manner; anti-SAA1 peptide (40-63) F(ab)2 fragments showed the proposed Ca2+-binding tetrapeptide (Gly48-Pro49-Gly50-Cys51) is not responsible, and SAA1 does not directly bind Ca2+ ions.\",\n      \"method\": \"In vitro monocyte stimulation, eicosanoid measurement, peptide antibody inhibition, Ca2+ binding assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assay with specific peptide inhibitors and negative Ca2+-binding result, single lab, multiple eicosanoid endpoints\",\n      \"pmids\": [\"9428637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Mouse SAA1.1 is fibrillogenic in vitro and causes amyloid deposition in vivo when expressed via adenoviral vector in CE/J mice, while SAA2.2 (the composite isoform in CE/J mice) cannot form fibrils and does not induce amyloid; mixing SAA2.2 with SAA1.1 does not inhibit SAA1.1 fibrillogenesis, demonstrating that CE/J amyloid resistance is due to structural inability of SAA2.2 to form fibrils.\",\n      \"method\": \"Recombinant protein expression, in vitro fibril formation assay, adenoviral vector-mediated in vivo expression, amyloid induction model\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of fibrillogenesis plus in vivo adenoviral expression with genetic isoform specificity, multiple orthogonal methods\",\n      \"pmids\": [\"11140693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Transgenic overexpression of acute-phase SAA1.1 at moderate levels did not significantly alter ApoA-I or HDL cholesterol levels, but high-level adenoviral SAA1.1 expression produced ~10% larger HDL particles; constitutive SAA4 expression increased HDL size (~10%), VLDL levels (20-fold), and triglycerides (1.7-fold), indicating isoform-specific effects on lipoprotein metabolism.\",\n      \"method\": \"SAA1.1 transgenic mice with inducible metallothionein promoter, adenoviral vector overexpression, lipoprotein profiling\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — transgenic and adenoviral in vivo models with quantitative lipoprotein measurements, isoform comparison, single lab\",\n      \"pmids\": [\"10845870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Glucocorticoids induce SAA1 transcription in KB epithelial cells but not in HepG2 hepatoma cells when administered alone; this glucocorticoid effect on SAA1 in both cell lines is glucocorticoid receptor-dependent, demonstrating tissue-specific and receptor-dependent transcriptional regulation of SAA1.\",\n      \"method\": \"RT-PCR mRNA quantification, glucocorticoid/cytokine treatments, receptor dependency analysis in hepatoma and epithelial cell lines\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — comparison across two cell types with receptor-dependency confirmation, single lab\",\n      \"pmids\": [\"12938239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SAA activates human mast cells to produce TNF-α and IL-1β in a dose-dependent manner; mast cell tryptase (but not chymase) cleaves SAA to release a highly amyloidogenic N-terminal fragment; intact mast cells degrade SAA and generate protofibrillar intermediates, implicating mast cells in AA amyloidosis pathogenesis.\",\n      \"method\": \"HMC-1 cell culture with rhSAA, ELISA, gel electrophoresis, LC-MS for degradation products, electron microscopy for protofibril detection\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — enzymatic cleavage assay with purified proteases, MS identification of fragments, functional cytokine readout, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16483749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD36, a class B scavenger receptor, functions as an SAA receptor mediating SAA uptake and pro-inflammatory signaling; SAA (but not other apolipoproteins) induces 10–50-fold increase in IL-8 secretion in CD36-overexpressing HEK293 cells; SAA-mediated signaling is primarily through JNK and ERK1/2 MAPK pathways; cd36−/− rat macrophages show 60–75% reduction in SAA-induced cytokine secretion; HDL-associated SAA neutralizes the effect.\",\n      \"method\": \"Stable transfection of CD36 in HeLa/HEK293 cells, fluorescent SAA uptake assay, ELISA for cytokines, MAPK phosphorylation assay, NF-κB/MAPK inhibitor studies, cd36−/− rat macrophages/Kupffer cells, CD36 peptide blocking\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods including overexpression, knockout cells, inhibitors, and blocking peptides across multiple cell types, single lab with comprehensive evidence\",\n      \"pmids\": [\"20075072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Lipid-poor (recombinant or purified) SAA stimulates pro-inflammatory cytokine (G-CSF) production in mouse J774 macrophages via TLR2, but HDL-associated SAA fails to stimulate cytokine production; in vivo adenoviral expression of mouse SAA in SAA-deficient mice did not elevate G-CSF at peak SAA levels, leaving physiological cytokine-inducing role of SAA in vivo ambiguous.\",\n      \"method\": \"J774 cell stimulation with lipid-poor rSAA and HDL-associated SAA, TLR2/4 neutralizing antibodies, adenoviral SAA expression in SAA-deficient mice, ELISA\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — TLR2 identified with neutralizing antibodies, in vivo adenoviral model, lipidation state comparison, single lab\",\n      \"pmids\": [\"23165195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SAA promotes differentiation of human monocytes into a distinct CD11c(high)CD11b(high) macrophage phenotype in vitro and in vivo (mouse airway challenge model); ALX/FPR2 antagonist WRW4 reduced IL-6 and IL-1β but not phagocytic activity; blocking CSF-1R signaling reduced CD11c(high)CD11b(high) macrophages by 71% and neutrophilic inflammation by 80%, placing SAA-driven macrophage differentiation downstream of CSF-1R.\",\n      \"method\": \"Human monocyte culture with SAA, FPR2 antagonist (WRW4), CSF-1R inhibitor, BALB/c mouse airway SAA challenge, flow cytometry, ELISA\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition of two receptors in vitro and in vivo, defined macrophage phenotype by flow cytometry, single lab\",\n      \"pmids\": [\"24846388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SAA1.1 and SAA1.3 isoforms, but not SAA1.5, suppress tumor formation and angiogenesis in nasopharyngeal carcinoma (NPC) cell lines in vitro and in vivo; secreted SAA1.1 and SAA1.3 block cell adhesion and induce apoptosis in vascular endothelial cells; SAA1.5 shows weaker binding affinity to αVβ3 integrin and lacks antiangiogenic/apoptotic function.\",\n      \"method\": \"Restoration of SAA1 isoforms in SAA1-deficient NPC cell lines, tumor formation assays in vitro/in vivo, endothelial cell apoptosis assay, αVβ3 integrin binding assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple isoforms tested, integrin binding assay, in vitro and in vivo tumor suppression, endothelial cell apoptosis, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"24608426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HDL counter-regulates SAA-induced sPLA2-IIE and sPLA2-V expression and secretion in murine macrophages in a dose-dependent manner; HDL also suppresses SAA-induced HMGB1 release, NO production, autophagy activation, and cytokine/chemokine secretion via TLR4-dependent signaling.\",\n      \"method\": \"RAW264.7 and primary macrophage culture, SAA and HDL treatment, ELISA, western blot for sPLA2 isoforms and signaling molecules, TLR4 functional dependence assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dose-dependent HDL counter-regulation shown for multiple endpoints, TLR4 dependence established, single lab\",\n      \"pmids\": [\"27898742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Heparin interacts with both ApoA-I and SAA in HDL from inflamed mice, forming complex aggregates; mass spectrometry of crosslinked HDL-SAA particles detected multiple crosslinks between ApoA-I and SAA indicating close proximity (within 25 Å) on the HDL surface.\",\n      \"method\": \"Gel electrophoresis, chemical crosslinking, mass spectrometry of crosslinked peptides\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — crosslinking MS provides structural proximity data, single lab, limited functional validation\",\n      \"pmids\": [\"27105909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SR-BII (splice variant of SR-BI) functions as an SAA receptor mediating SAA uptake (~3-fold increase) and pro-inflammatory IL-8 secretion (~3–3.5-fold increase) in transfected cells; SAA activates ERK1/2, p38, and JNK MAPK pathways via SR-BII; transgenic mice overexpressing hSR-BII showed ~2–5-fold higher inflammatory mediator expression in liver and kidney after SAA injection compared to wild-type.\",\n      \"method\": \"Stable transfection of hSR-BII in HeLa/HEK293 cells, fluorescent SAA uptake assay, ELISA, MAPK phosphorylation assay, transgenic mouse in vivo SAA challenge, histology, plasma transaminase measurement\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — overexpression and transgenic in vivo models, multiple signaling pathway readouts, in vitro and in vivo concordance, single lab\",\n      \"pmids\": [\"28423002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"COOH-terminal SAA1 fragments (SAA1(46-112) bovine; SAA1(47-104) human) fail to directly chemoattract leukocytes, induce chemokines, or stimulate ERK signaling, but potently synergize with CCL3 (monocyte migration) and CXCL8 (neutrophil chemotaxis) via FPR2; SAA1(47-104) desensitizes intact SAA1α/CXCL8 synergy, and WRW4 (FPR2 antagonist) completely blocks synergy, confirming FPR2 as the mediating receptor.\",\n      \"method\": \"Protein purification from bovine serum, chemical synthesis of peptides, chemotaxis assays, ERK signaling assay, FPR2 antagonist (WRW4) blocking, in vivo mouse peritoneal neutrophil recruitment assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — purified natural fragment plus synthetic peptide, multiple cell types, FPR2 receptor confirmed by receptor desensitization and antagonist, in vitro and in vivo concordance\",\n      \"pmids\": [\"29371208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SAA1 increases NOX4/ROS production and activates the p38MAPK/NF-κB pathway to promote LPS-induced inflammatory cytokine release (IL-1β, IL-6, IL-8, IL-17, TNF-α, MCP-1) in vascular smooth muscle cells; both SAA1 siRNA and NOX4 siRNA attenuate this pathway, and combined knockdown shows no additive effect, placing SAA1 upstream of NOX4 in this signaling cascade.\",\n      \"method\": \"SAA1 siRNA, NOX4 siRNA, recombinant SAA1 protein treatment, lucigenin-enhanced chemiluminescence for O2− and NADPH oxidase activity, qRT-PCR, western blot for p38MAPK/NF-κB pathway proteins\",\n      \"journal\": \"BMC molecular and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via double knockdown placing SAA1 upstream of NOX4, pathway validated by western blot, single lab\",\n      \"pmids\": [\"31216990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SAA1/Saa1 silencing inhibits palmitate-induced insulin resistance in Huh7 cells and HFD-induced insulin resistance in mice via suppression of the NF-κB pathway; SAA1 promotes NF-κB p65 nuclear translocation both in vitro and in vivo, linking SAA1 to hepatic insulin signaling impairment.\",\n      \"method\": \"SAA1 siRNA in Huh7 cells, HFD mouse model with Saa1 silencing, NF-κB inhibitor (BAY 11-7082), RT-qPCR, western blot, glucose tolerance test, insulin sensitivity assay, NF-κB p65 nuclear/cytoplasmic fractionation\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo concordant KD results, NF-κB p65 nuclear translocation directly measured, single lab\",\n      \"pmids\": [\"31060494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Purified recombinant SAA1 (hrSAA1) free of LPS, lipoprotein, and formylated peptide contaminants retains leukocyte-recruiting capacity in vivo and synergy with other chemoattractants via FPR2, and promotes monocyte survival; however, hrSAA1 lacks most cytokine-inducing, MMP-9 release, ROS generation, and macrophage differentiation activities previously attributed to SAA1, indicating these TLR-mediated effects were due to bacterial contaminants in commercial rSAA1 preparations.\",\n      \"method\": \"RP-HPLC purification of rSAA1, endotoxin removal, chemotaxis assays, cytokine ELISA, MMP-9 measurement, ROS assay, macrophage differentiation, in vivo leukocyte recruitment, FPR2 activation assay\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous purification with removal of contaminants, multiple orthogonal functional assays, resolves contradictions in the field\",\n      \"pmids\": [\"32477346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SAA1 is synthesized de novo in human placental villous trophoblasts; SAA1 expression increases upon syncytialization and with LPS, TNF-α, and cortisol treatment; SAA1 treatment of syncytiotrophoblasts increases IL-1β, IL-8, TNF-α, COX-2 expression and PGF2α production; intraperitoneal SAA1 injection in mice induces preterm birth and increases inflammatory mediators in placenta.\",\n      \"method\": \"RT-PCR, western blot, immunohistochemistry in human placenta; syncytialization cell model; cytokine ELISA; in vivo SAA1 injection mouse model with preterm birth readout\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo concordant results, specific inflammatory gene induction measured, single lab\",\n      \"pmids\": [\"32582166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SAA1 acts as a hepatic endogenous chemokine for TLR2 on hepatic stellate cells (HSCs), recruiting them toward injury loci; SAA1/TLR2 signaling stimulates Rac GTPases through PI3K-dependent pathways, induces MLC phosphorylation (pSer19), and drives actin filament remodeling and directional migration; genetic TLR2 deletion and pharmacological PI3K inhibition both abolish MLCpSer19 phosphorylation and HSC migration.\",\n      \"method\": \"Gene manipulation (TLR2 knockout, SAA1 overexpression/knockdown) in cell and mouse models, PI3K pharmacological inhibition, MLC phosphorylation western blot, Rac GTPase activity assay, migration assay\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — genetic and pharmacological epistasis, defined signaling pathway with specific phosphorylation readout, in vitro and in vivo concordance, single lab\",\n      \"pmids\": [\"34113824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SAA1 promotes intrahepatic platelet aggregation and liver inflammation in NAFLD; SAA1-treated platelets show increased aggregation sensitivity, activation, and adhesion partly via TLR2 signaling; SAA1 knockdown in vivo reduces intrahepatic platelet aggregation and ameliorates fatty liver inflammation in HFD mice.\",\n      \"method\": \"SAA1 recombinant protein platelet treatment, TLR2 inhibitor blocking, platelet aggregation/activation/adhesion assays, in vivo SAA1 knockdown in HFD mice, liver histology, inflammation markers\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — TLR2 dependence shown with inhibitor, in vitro and in vivo concordance, single lab\",\n      \"pmids\": [\"33813276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SAA1 is transcriptionally activated by STAT3 and directly binds VIMP to inhibit the Derlin-1/VCP/VIMP complex, preventing misfolded protein degradation and causing endoplasmic reticulum stress (elevated GRP78), which promotes renal interstitial fibrosis.\",\n      \"method\": \"Bioinformatics prediction confirmed by SAA1 expression in UUO mouse model and TGF-β-induced HK2 cells, STAT3 ChIP/transcriptional activation assays, co-immunoprecipitation of SAA1 with VIMP, ER stress markers (GRP78), siRNA knockdown\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP binding partner identified, STAT3 transcriptional activation and downstream ER stress mechanism, single lab\",\n      \"pmids\": [\"34597680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SAA1 promotes pro-labour inflammatory mediators (IL-8, IL-6, CXCL5, CCL2, ICAM1, ICAM5, COX-2, PGE2) in human primary myometrial cells through activation of the YAP (Yes-associated protein) pathway; SAA1 knockdown reduces phospho-YAP and downstream pro-inflammatory gene expression, while YAP overexpression reverses the knockdown effect.\",\n      \"method\": \"SAA1 siRNA in human primary myometrial cells, YAP overexpression rescue experiment, western blot for pYAP, cytokine/mediator ELISA and RT-PCR\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue (YAP overexpression reversing SAA1 KD) establishes pathway placement, single lab\",\n      \"pmids\": [\"33719002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A T>C mutation in the SAA1 promoter (chr11:18287683) doubles basal SAA1 promoter activity and causes hereditary amyloid A amyloidosis with autosomal dominant inheritance; the mutation is linked to the amyloidogenic SAA1.1 haplotype, and tocilizumab (anti-IL-6 receptor antibody) has beneficial effects when given early.\",\n      \"method\": \"SAA1 promoter activity assay (luciferase or equivalent), genetic linkage analysis (LOD score >5), SAA level measurement in genetically affected and unaffected family members, amyloid composition analysis\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — functional promoter activity assay plus genetic linkage with LOD >5, amyloid composition confirmed as SAA1.1, in a characterized family\",\n      \"pmids\": [\"34560138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SAA1 is upregulated in gastric cancer-associated fibroblasts (CAFs) due to increased H3K27ac (active enhancer mark) at the SAA1 promoter and two far upstream enhancer regions; BET bromodomain inhibitors (JQ1 and mivebresib) decrease SAA1 expression and tumor-promoting effects; conditioned medium from SAA1-overexpressing NCAFs increases gastric cancer cell migration comparably to CAF-CM, and CAF-CM tumor promotion is mostly abolished by SAA1 knockdown.\",\n      \"method\": \"ChIP-qPCR for H3K27ac, SAA1 overexpression in NCAFs, SAA1 knockdown in CAFs, conditioned medium migration assay, BET inhibitor treatment\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR establishes enhancer mechanism, gain- and loss-of-function migration assays with conditioned medium, single lab\",\n      \"pmids\": [\"33284950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Ovarian granulosa cells produce SAA1, which can induce its own expression (feedforward loop); excessive SAA1 attenuates insulin-stimulated GLUT4 membrane translocation and glucose uptake via induction of PTEN and subsequent inhibition of Akt phosphorylation, effects blocked by TLR2/4 and NF-κB inhibitors.\",\n      \"method\": \"Primary granulosa cell culture, SAA1 treatment, GLUT4 membrane translocation assay, glucose uptake assay, western blot for PTEN and phospho-Akt, TLR2/4 and NF-κB inhibitor blocking experiments\",\n      \"journal\": \"Reproductive biology and endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway from SAA1 to TLR2/4-NF-κB-PTEN-Akt-GLUT4 established with inhibitors, single lab\",\n      \"pmids\": [\"34980155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SAA1 promotes cancer stem cell transformation and drives type 2 immunity (Th2 polarization) via the P2X7 receptor, restricting anti-tumor immunity and promoting tumor fibrosis; anti-SAA neutralization antibody reverses these effects in patient-derived organoid/PBMC co-culture model.\",\n      \"method\": \"scRNA-seq (public dataset), ex vivo patient-derived organoid/PBMC co-culture, anti-SAA neutralizing antibody, P2X7 receptor inhibition, immune cell polarization assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — P2X7 dependence demonstrated with inhibition, neutralizing antibody rescue, patient-derived model, single lab\",\n      \"pmids\": [\"37925492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Circadian clock BMAL1 suppresses SAA1 transcription in myeloid cells via the Rev-erbα-C/EBPβ axis: Rev-erbα (reduced in Bmal1-deficient cells) inhibits C/EBPβ binding to the Saa1 promoter; Bmal1 deficiency enhances C/EBPβ-Saa1 promoter binding and SAA1 expression; SAA1 in turn promotes noncanonical inflammasome-mediated pyroptosis; type 1 IFN receptor signaling is required for IFN-β/poly(I:C)-induced SAA1 production.\",\n      \"method\": \"Myeloid-specific Bmal1 knockout mice, transcriptome analysis, ChIP for C/EBPβ at Saa1 promoter, Rev-erbα inhibitor (SR8278), exogenous SAA1 administration, noncanonical inflammasome pyroptosis assays\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP directly shows C/EBPβ promoter occupancy, genetic KO and pharmacological inhibition of Rev-erbα confirm pathway, type 1 IFN receptor requirement established, multiple orthogonal methods in one study\",\n      \"pmids\": [\"38297162\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SAA1 is a liver-derived (and extrahepatic) acute-phase apolipoprotein that circulates primarily bound to HDL3 via ApoA-I and ApoA-II; its lipidation state critically determines bioactivity—lipid-free SAA1 signals through receptors including FPR2, CD36, SR-BII, and TLR2 to activate JNK/ERK/p38 MAPK and NF-κB pathways driving pro-inflammatory cytokine production, leukocyte chemotaxis (synergizing with CXCL8 and CCL3), macrophage differentiation (via CSF-1R), platelet activation, hepatic stellate cell migration (via PI3K/Rac/MLC), and insulin resistance (via PTEN/Akt inhibition), whereas HDL-associated SAA1 lacks most of these activities; SAA1 transcription is induced by IL-1/cytokines, STAT3, and C/EBPβ (regulated by the circadian clock via Rev-erbα-BMAL1), and is suppressed by glucocorticoid receptor-dependent mechanisms in a tissue-specific manner; the SAA1.1 isoform is selectively amyloidogenic and fibril-forming in vitro and in vivo, a property exploited by mast cell tryptase to generate amyloidogenic N-terminal fragments, while isoforms SAA1.1 and SAA1.3 additionally suppress angiogenesis through αVβ3 integrin binding.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SAA1 is an acute-phase apolipoprotein that circulates bound to high-density lipoprotein HDL3, where it associates with ApoA-I and ApoA-II and remodels HDL toward larger, phospholipid-depleted, triglyceride-enriched particles [#0, #3, #8, #16]. Its hepatic synthesis is directly induced by the cytokine IL-1 and is secreted through the classical secretory pathway, while the gene family shows tissue-specific expression with distinct hepatic versus macrophage compartments [#2, #4]. SAA1 bioactivity is governed by its lipidation state: lipid-free SAA1 engages cell-surface receptors to drive pro-inflammatory signaling, whereas HDL association neutralizes or counter-regulates most of these effects [#11, #12, #15]. The scavenger receptors CD36 and SR-BII mediate SAA1 uptake and trigger JNK, ERK1/2, and p38 MAPK signaling with downstream cytokine/chemokine output, and SAA1 also signals through TLR2 to recruit and activate hepatic stellate cells (via PI3K/Rac/MLC phosphorylation), platelets, and to impair insulin signaling through NF-\\u03baB-dependent mechanisms [#11, #17, #23, #24, #20]. A rigorous re-purification study established that much of the cytokine-inducing, ROS-generating, and macrophage-differentiating activity attributed to recombinant SAA1 reflected bacterial contaminants, while genuine SAA1 retains FPR2-dependent leukocyte recruitment and synergy with chemokines such as CXCL8 and CCL3 \\u2014 an activity mediated by intact protein rather than C-terminal fragments [#21, #18]. Distinct from its inflammatory signaling, the SAA1.1 isoform is intrinsically fibrillogenic and amyloidogenic in vitro and in vivo, and mast cell tryptase cleaves SAA1 to release a highly amyloidogenic N-terminal fragment, defining SAA1 as the precursor of AA amyloidosis; a promoter mutation that doubles SAA1 expression causes autosomal dominant hereditary amyloid A amyloidosis [#7, #10, #27]. SAA1 transcription is controlled combinatorially by STAT3, glucocorticoid receptor (in a tissue-specific manner), enhancer acetylation, and the circadian Rev-erb\\u03b1\\u2013C/EBP\\u03b2 axis downstream of BMAL1 [#9, #25, #28, #31]. Isoform-specific functions extend to angiogenesis suppression, where SAA1.1 and SAA1.3 (but not SAA1.5) bind \\u03b1V\\u03b23 integrin to block endothelial adhesion and induce apoptosis [#14].\",\n  \"teleology\": [\n    {\n      \"year\": 1977,\n      \"claim\": \"Established the fundamental biochemical identity of SAA as an HDL-associated apolipoprotein rather than a free serum protein, defining the lipoprotein context for all later function.\",\n      \"evidence\": \"Ultracentrifugation and density gradient fractionation of human serum with immunochemical analysis\",\n      \"pmids\": [\"198813\", \"301900\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which HDL apolipoproteins SAA contacts directly\", \"No functional consequence of HDL binding established\"]\n    },\n    {\n      \"year\": 1982,\n      \"claim\": \"Identified the liver as a direct cytokine target for SAA induction, explaining the acute-phase rise in SAA during inflammation.\",\n      \"evidence\": \"In vitro mouse hepatocyte culture with purified leukocytic pyrogen (IL-1), immunoprecipitation, and cell-free translation\",\n      \"pmids\": [\"6807176\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not define transcription factors transducing the IL-1 signal\", \"Single inducer tested\"]\n    },\n    {\n      \"year\": 1985,\n      \"claim\": \"Showed SAA enrichment causally remodels HDL particle composition and size, demonstrating that SAA is not a passive passenger but alters lipoprotein structure.\",\n      \"evidence\": \"Biophysical fractionation plus in vitro HDL-SAA reconstitution\",\n      \"pmids\": [\"4086942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of altered HDL for inflammation or lipid transport not tested\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Revealed tissue-specific and isoform-specific expression of the SAA gene family, distinguishing hepatic SAA1/SAA2 from macrophage SAA3 and linking expression shifts to amyloidosis.\",\n      \"evidence\": \"Comparative mRNA expression across mouse tissues in acute-phase and amyloidosis models\",\n      \"pmids\": [\"3680951\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"mRNA-level only\", \"Does not address human SAA1 isoform specifics\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Defined SAA1 protein polymorphisms and common N-terminal post-translational processing, providing the molecular basis for later isoform-specific functional differences.\",\n      \"evidence\": \"Multiple orthogonal mass spectrometry methods and amino acid analysis\",\n      \"pmids\": [\"8512321\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of the polymorphisms not addressed\", \"No link to amyloidogenicity at this stage\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrated that amyloidogenicity is an intrinsic structural property of the SAA1.1 isoform, separating fibril-forming from non-fibril-forming SAA variants.\",\n      \"evidence\": \"Recombinant fibril formation assays plus adenoviral in vivo expression and amyloid induction in mice\",\n      \"pmids\": [\"11140693\", \"10845870\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify cellular proteases or cofactors that initiate fibrillogenesis in vivo\", \"Mechanism distinguishing fibril-prone from resistant isoforms structurally undefined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Linked mast cell biology to amyloidosis by showing tryptase cleaves SAA into an amyloidogenic N-terminal fragment, defining a proteolytic route to fibril precursors.\",\n      \"evidence\": \"HMC-1 mast cell culture, protease cleavage assays, LC-MS fragment identification, and electron microscopy of protofibrils\",\n      \"pmids\": [\"16483749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of mast-cell-generated fragments to human amyloidosis not established\", \"Cytokine readouts may reflect impure preparations\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified CD36 as a functional SAA receptor coupling SAA uptake to JNK/ERK MAPK-driven cytokine production, and showed HDL association neutralizes signaling.\",\n      \"evidence\": \"CD36 overexpression and knockout cells, uptake and cytokine assays, MAPK phosphorylation, and blocking peptides\",\n      \"pmids\": [\"20075072\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytokine effects later complicated by contaminant concerns in rSAA\", \"Relative contribution of CD36 versus other receptors in vivo unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established that lipidation state determines SAA signaling, with lipid-poor but not HDL-bound SAA activating TLR2, while questioning the in vivo physiological cytokine role.\",\n      \"evidence\": \"J774 macrophage stimulation with lipid-poor versus HDL-associated SAA, TLR2 neutralizing antibodies, and adenoviral expression in SAA-deficient mice\",\n      \"pmids\": [\"23165195\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo cytokine induction not reproduced\", \"Did not exclude preparation contaminants\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined two non-redundant SAA1 activities: receptor-driven macrophage differentiation downstream of CSF-1R/FPR2, and isoform-specific anti-angiogenesis via \\u03b1V\\u03b23 integrin binding.\",\n      \"evidence\": \"Monocyte differentiation with FPR2 and CSF-1R inhibitors plus airway model; isoform restoration in NPC cells with integrin binding and endothelial apoptosis assays\",\n      \"pmids\": [\"24846388\", \"24608426\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Macrophage differentiation activity later attributed partly to contaminants\", \"Structural basis of isoform-selective integrin binding undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mapped HDL counter-regulation of SAA inflammatory signaling and resolved the structural proximity of SAA to ApoA-I on the HDL surface.\",\n      \"evidence\": \"Macrophage HDL counter-regulation assays with TLR4 dependence; chemical crosslinking mass spectrometry of HDL-SAA particles\",\n      \"pmids\": [\"27898742\", \"27105909\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which HDL physically blocks receptor engagement not resolved\", \"Crosslinking provides proximity but not a high-resolution structure\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified SR-BII as a second scavenger-receptor route for SAA uptake and tri-MAPK activation, corroborated by transgenic in vivo inflammatory responses.\",\n      \"evidence\": \"SR-BII overexpression cells with uptake/cytokine/MAPK assays and hSR-BII transgenic mouse SAA challenge\",\n      \"pmids\": [\"28423002\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contribution of SR-BII versus CD36 and TLR2 unresolved\", \"Did not address lipidation-state dependence\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed that the leukocyte-recruiting function of SAA1 operates chiefly by FPR2-dependent synergy with chemokines, and that C-terminal fragments cannot act alone.\",\n      \"evidence\": \"Purified natural and synthetic SAA1 fragments, chemotaxis assays, FPR2 desensitization and antagonist blocking, and in vivo neutrophil recruitment\",\n      \"pmids\": [\"29371208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous source of the synergizing fragments in vivo not defined\", \"Does not address direct receptor structural engagement\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved long-standing contradictions by demonstrating that purified contaminant-free SAA1 retains FPR2-mediated chemotaxis but lacks most TLR-attributed cytokine, ROS, MMP-9, and differentiation activities, reframing the field's interpretation of SAA1 function.\",\n      \"evidence\": \"RP-HPLC-purified endotoxin-free rSAA1 across chemotaxis, cytokine, ROS, MMP-9, differentiation, and in vivo recruitment assays\",\n      \"pmids\": [\"32477346\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not exclude that endogenous SAA1 modifications confer additional activities\", \"Receptor specificity for surviving activities partially defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Expanded SAA1 into a tissue-remodeling and metabolic effector, signaling via TLR2 to drive hepatic stellate cell migration, platelet aggregation, and insulin resistance, with promoter mutation establishing a direct Mendelian amyloidosis link.\",\n      \"evidence\": \"TLR2 genetic/pharmacological epistasis with MLC and Rac readouts; platelet aggregation assays; SAA1 silencing in HFD mice; STAT3 ChIP and VIMP co-IP; promoter luciferase plus family linkage (LOD>5)\",\n      \"pmids\": [\"34113824\", \"33813276\", \"31060494\", \"31216990\", \"34597680\", \"34560138\", \"33719002\", \"33284950\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Multiple downstream pathways shown in distinct single-lab disease models\", \"Whether lipidation state modulates these effects often untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Detailed a receptor-to-metabolism cascade in which SAA1 induces PTEN to inhibit Akt and impair GLUT4-dependent glucose uptake through TLR2/4-NF-\\u03baB signaling, with feedforward self-induction.\",\n      \"evidence\": \"Granulosa cell culture, GLUT4 translocation and glucose uptake assays, PTEN/phospho-Akt western blots, and TLR/NF-\\u03baB inhibitor blocking\",\n      \"pmids\": [\"34980155\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell type and lab\", \"In vivo metabolic relevance not established here\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placed SAA1 under circadian control by showing BMAL1 represses SAA1 via the Rev-erb\\u03b1\\u2013C/EBP\\u03b2 axis, coupling rhythmic transcription to SAA1-driven inflammasome pyroptosis.\",\n      \"evidence\": \"Myeloid Bmal1 knockout mice, C/EBP\\u03b2 ChIP at the Saa1 promoter, Rev-erb\\u03b1 inhibition, and pyroptosis assays\",\n      \"pmids\": [\"38297162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human relevance of myeloid circadian SAA1 regulation untested\", \"Receptor mediating pyroptotic SAA1 action not pinned down\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the multiple candidate receptors (FPR2, CD36, SR-BII, TLR2, P2X7, \\u03b1V\\u03b23) are selected in vivo, and how lipidation state, isoform identity, and proteolytic processing jointly dictate which SAA1 activity dominates in a given tissue.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified structural model of SAA1-receptor engagement\", \"Physiological versus contaminant-driven activities not fully partitioned in vivo\", \"Relative receptor usage across tissues undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 3, 8, 16]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [11, 17, 18, 23]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [7, 10]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [11, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11, 17, 18, 21]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [2, 31]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 10, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 23, 29]}\n    ],\n    \"complexes\": [\n      \"HDL (HDL3)\"\n    ],\n    \"partners\": [\n      \"APOA1\",\n      \"APOA2\",\n      \"CD36\",\n      \"SCARB1\",\n      \"TLR2\",\n      \"FPR2\",\n      \"ITGAV/ITGB3\",\n      \"VIMP (SELENOS)\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":8,"faith_total":8,"faith_pct":100.0}}